
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and ... Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 7.539 | 7.539 | 7.539 | 0 | 0 | CS |
4 | 0 | 0 | 7.539 | 7.539 | 7.539 | 0 | 0 | CS |
12 | 0 | 0 | 7.539 | 7.539 | 7.539 | 0 | 0 | CS |
26 | 1.624 | 27.4556213018 | 5.915 | 8.3965 | 5.6 | 860226 | 6.93157351 | CS |
52 | 4.298 | 132.613390929 | 3.241 | 14.595 | 3.01 | 5197266 | 7.19129591 | CS |
156 | -622.461 | -98.8033333333 | 630 | 1470 | 2.835 | 3581436 | 80.28095818 | CS |
260 | -2109.961 | -99.6439669421 | 2117.5 | 5862.5 | 2.835 | 2666378 | 368.07818439 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.